Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab-Reference-Cited by-同舟云学术

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab

Published:2018-10 Issue: Volume:41 Page:1-7
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Jacquinot Quentin,Paget-Bailly Sophie,Fumoleau Pierre,Romieu Gilles,Pierga Jean Yves,Espié Marc,Lortholary Alain,Nabholtz Jean Marc,Mercier Celine Faure,Pauporté Iris,Henriques Julie,Pivot Xavier

Funder

French National Cancer Institute

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference39 articles.

1. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial;Smith;Lancet Lond Engl,2007

2. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

4. Four-Year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31;Perez;J Clin Oncol,2011

5. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study;Pivot;Eur J Canc,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review;Cancers;2023-06-22

2. Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab;Frontiers in Cardiovascular Medicine;2022-09-23

3. Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer;Frontiers in Pharmacology;2021-11-01

4. Cardiovascular Toxicity Induced by Chronic Vincristine Treatment;Frontiers in Pharmacology;2021-07-21

5. Cardiotoxicity in HER2-positive breast cancer patients;Heart Failure Reviews;2021-01-06